KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer

This study examined the status of KRAS and BRAF mutations, in relation to extracellular signal-regulated protein kinase (ERK) activation in 58 ovarian carcinomas to clarify the clinicopathological and prognostic significance of KRAS/BRAF mutations. Somatic mutations of either KRAS or BRAF were ident...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakayama, N, Nakayama, K, Yeasmin, S, Ishibashi, M, Katagiri, A, Iida, K, Fukumoto, M, Miyazaki, K
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2607229/
https://www.ncbi.nlm.nih.gov/pubmed/19018267
http://dx.doi.org/10.1038/sj.bjc.6604783

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2607229/
https://www.ncbi.nlm.nih.gov/pubmed/19018267
http://dx.doi.org/10.1038/sj.bjc.6604783

Ejemplares similares